Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor —ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated s...

Source: Health Economics Review - February 18, 2023 Category: Health Management Authors: Mariano A. Giorgi, Carlos P. Boissonnet, Paula Soledad Luque, Jimena Piastrella, Carlos Porley, Fernanda Ditata and Sergio Volman Tags: Research Source Type: research